Oncotarget

Reviews:

Targeting EIF4F complex in non-small cell lung cancer cells

Lu Dai, Zhen Lin, Yueyu Cao, Yihan Chen, Zengguang Xu and Zhiqiang Qin _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:55731-55735. https://doi.org/10.18632/oncotarget.18413

Metrics: PDF 2195 views  |   HTML 3360 views  |   ?  


Abstract

Lu Dai1,2,3, Zhen Lin4, Yueyu Cao3, Yihan Chen3, Zengguang Xu3 and Zhiqiang Qin1,2,3

1Department of Genetics, Louisiana State University Health Sciences Center, Louisiana Cancer Research Center, New Orleans, LA 70112, USA

2Department of Pediatrics, East Hospital, Tongji University School of Medicine, Shanghai 200120, China

3Research Center for Translational Medicine and Key Laboratory of Arrhythmias, East Hospital, Tongji University School of Medicine, Shanghai 200120, China

4Department of Pathology, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, LA 70112, USA

Correspondence to:

Zhiqiang Qin, email: [email protected]

Zengguang Xu, email: [email protected]

Keywords: EIF4F, EIF4A, EIF4E, EIF4G, eukaryotic initiation factors

Received: May 18, 2017     Accepted: May 29, 2017     Published: June 08, 2017

ABSTRACT

Non-small cell lung cancer (NSCLC) accounts for about 85–90% of lung cancer cases, which represents the leading cause of cancer-related death in the world. The majority of lung cancer patients doesn't respond well to conventional chemo-/radio-therapeutic regimens and have a poor prognosis. The recent introduction of targeted therapy and immunotherapy gives new hopes to NSCLC patients, but their outcome/prognosis is far from satisfactory. The translation initiation EIF4F complex has been shown to play important roles in cancer progression, but its functional role and therapeutic effect in lung cancers especially NSCLC remain largely unknown. In this current review, we summarize recent findings regarding the role of EIF4F complex in NSCLC progression and targeted therapy potentials. We also discuss the unanswered questions and future directions in this field.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18413